4D Molecular Therapeutics
FDMT
153 hedge funds and large institutions have $402M invested in 4D Molecular Therapeutics in 2025 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 56 increasing their positions, 37 reducing their positions, and 12 closing their positions.
310% more call options, than puts
Call options by funds: $1.13M | Put options by funds: $275K
167% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 12
51% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 37
16% more capital invested
Capital invested by funds: $346M → $402M (+$55.9M)
14% more funds holding
Funds holding: 134 → 153 (+19)
8.82% more ownership
Funds ownership: 84.68% → 93.51% (+8.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$29.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$18.1M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$16.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.6M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$10.7M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.73M |
| 3 |
Two Sigma Advisers
New York
|
-$2.78M |
| 4 |
JP Morgan Chase
New York
|
-$2.37M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.72M |
FDMT Hedge Fund Activity: Q4 2025 in Review
153 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q4 2025, worth a combined $402M — up 16% from $346M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new FDMT positions and 12 closed out — a net gain of 20 holders — while 56 added to existing stakes and 37 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $29.2M. The largest seller was Millennium Management, cutting an estimated $10.7M.
- 153 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q4 2025, up from 134 in Q3 2025.
- Funds reported $402M of 4D Molecular Therapeutics stock for Q4 2025, up 16% quarter-over-quarter.
- 32 funds opened new 4D Molecular Therapeutics positions in Q4 2025 and 12 closed out, a net change of +20 holders.
- The largest 4D Molecular Therapeutics buyer in Q4 2025 was Janus Henderson Group, an estimated $29.2M added.
- The largest 4D Molecular Therapeutics seller in Q4 2025 was Millennium Management, an estimated $10.7M sold.
Based on aggregated 13F filings for Q4 2025.